Cell Source, Inc.
OTC: CLCS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Itamar Shimrat
- Employees
- 1
- Headquarters
- New York City, United States
- IPO year
- 2014
- Market cap
- $37.4M
- Website
- https://www.cell-source.com
Loading CLCS…
Loading profile data…Frequently asked questions about CLCS
What does Cell Source, Inc. (CLCS) do?
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds a...
Where does CLCS trade?
Cell Source, Inc. (CLCS) trades on the Other OTC.
What sector is CLCS in?
Cell Source, Inc. (CLCS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cell Source, Inc.?
Itamar Shimrat is the chief executive officer of Cell Source, Inc. (CLCS).
Where is Cell Source, Inc. headquartered?
Cell Source, Inc. is headquartered in United States.
Does CLCS pay a dividend?
Cell Source, Inc. (CLCS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLCS go public?
Cell Source, Inc. (CLCS) completed its initial public offering in 2014.